CClinicalTrials.gg
CompletedNCT03248830Updated Oct 1, 2019

Non-invasive Hemoglobin Monitoring in Congenital Heart Diseased Children

An observational study in Congenital Heart Disease, sponsored by Cairo University. Completed at 1 site in Egypt. Open to participants aged 1 Month to 8 Years. Per ClinicalTrials.gov, last updated 2019-10-01.

Sponsored by Cairo University · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
56
Ages
1 Month to 8 Years
Sex
All
01

Study summary

The investigators will evaluate the accuracy of non-invasive hemoglobin monitor (Sp-Hb) compared to traditional laboratory hemoglobin (Lab-Hb) in children with congenital heart disease. The investigators will also compare the accuracy of Sp-Hb in cyanotic children to acyanotic children.

Read the detailed description

Blood hemoglobin is measured daily in clinical practice. Laboratory measurement (Lab-Hb) of is the gold standard for assessment of blood hemoglobin. Recently, non-invasive monitors had been introduced. Non-invasive measurement of hemoglobin (Sp-Hb) would save time and minimize the risk of infection. Blood sampling in children is usually more difficult and stressful; moreover, it also carries the risk of iatrogenic anemia.

Radical-7 (Masimo corporation, Irvine, CA) is a device that operates using the principle of co-oximetry . Radical-7 had been validated in various clinical purposes. Measurement of blood hemoglobin is an important application for Radical-7 device. Non-invasive hemoglobin (Sp-Hb) measurement has been frequently validated in adults; as well as in pediatric patients; however, its accuracy in children with congenital heart disease was not investigated. Congenital heart disease infants usually undergo major operations and frequently need transfusion of blood. Moreover, these patients have special circulatory physiology that might impact the device accuracy. It had been recently reported that the performance of co-oximetry in congenital heart disease children is poor in measurement of oxygen saturation specially at oxygen saturation under 75%; however, its accuracy in measurement of hemoglobin was not investigated yet. In this study, the investigators will evaluate the accuracy of Sp-Hb compared to traditional Lab-Hb in children with congenital heart disease. the investigators will also compare the accuracy of Sp-Hb in cyanotic children to acyanotic children.

02

Conditions studied

  • Congenital Heart Disease
03

In context

Heart Diseases

3,639 studies on the registry are indexed under Heart Diseases; 461 are open to participants now.

This study's enrollment of 56 is below the median of 294 across 1,241 observational studies indexed under Heart Diseases.

Browse Heart Diseases studies →

Lead sponsor

Cairo University is the lead sponsor of 4,780 studies on the registry; 1,427 are open to participants now.

Of its 36 completed or terminated interventional studies of FDA-regulated products, 5 (14%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Month to 8 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study will include children less than 8 years with congenital hear diseases scheduled for surgery or endo-vascular iintervention

Inclusion criteria

  • infants and children less than 8 years
  • with congenital heart disease

Exclusion criteria

Exclusion Criteria:

  • refusal of the patient surrogate to share in the study
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
56 participants (actual)
Patient registry
No

Interventions

  • Deviceradical-7 pulse co-oximeter

    Radical-7 pulse co-oximter will be applied to the patient through a special probe attached the the patient digit to measure blood hemoglobin

    Also known as: Masimo pulse co-oximeter

06

What researchers measure

Primary outcomes

  1. non-invasive hemoglobin

    the value of hemoglobin measured by radical-7 device in g/dL

    Time frame: 5 hours

Secondary outcomes

  1. laboratory hemoglobin

    the value of hemoglobin measured from a blood sample in the laboratory in g/dL

    Time frame: 5 hours

  2. perfusion index

    the percentage of perfusion index measured by radical-7 device

    Time frame: 5 hours

  3. plethysmography variability index

    the percentage of plethysmography variability index measured by radical-7 device

    Time frame: 5 hours

  4. systolic blood pressure

    systolic blood pressure measured in mmHg

    Time frame: 5 hours

  5. diastolic blood pressure

    diastolic blood pressure measured in mmHg

    Time frame: 5 hours

  6. oxygen saturation from radical-7 device

    oxygen saturation measured by radical-7 device

    Time frame: 5 hours

  7. oxygen saturation from arterial blood gases

    oxygen saturation measured from arterial blood gases

    Time frame: 5 hours

  8. heart rate

    number of heart beats per minute

    Time frame: 5 hours

07

Study locations

1 site
  • Cairo University
    Cairo, Egypt
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 1, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03248830
Lead sponsor
Cairo University
Responsible party
Ahmed Hasanin (Assistant professor, Cairo University) — Principal investigator
First posted
Aug 14, 2017
Start date
Feb 20, 2018
Primary completion
Aug 1, 2019
Completion
Sep 10, 2019
Last update
Oct 1, 2019

Study contacts

Ahmed Mukhtar, Professor
study director · Head of research committee section in anesthesia department

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion